gi.1/gii.4 bivalent vlp vaccine
Vaccineexperimental
Clinical trial activity
8 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02475278)
Timeline
Indications
Mechanism of action
- NorovirusImmunity, active
immunity, active - norovirus
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gi.1/gii.4
- gi.1/gii.4 bivalent vlp vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05626803 | Phase 2 | Dec 15, 2022 | Vaxart |
| NCT04941261 | Phase 2 | Jun 30, 2021 | Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd., China National Biotec Group Co., Ltd, National Vaccine and Serum Institute, China, Zhengzhou University |
| NCT05508178 | Phase 1 | Aug 17, 2020 | Ghent University, Icon Genetics |
| NCT04188691 | Phase 1 | Nov 28, 2019 | Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd., China National Biotec Group Co., Ltd, National Vaccine and Serum Institute, China, Zhengzhou University |
| NCT03039790 | Phase 2 | Feb 21, 2017 | Takeda |
| NCT02669121 | Phase 2 | Feb 17, 2016 | Takeda |
| NCT02153112 | Phase 2 | Jun 23, 2015 | Takeda |
| NCT02475278 | Phase 2 | Feb 1, 2015 | Takeda |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 4 | 4 | 1 | 2015 |
| Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd. | For profit | 2 | 0 | 2 | 2019 |
| China National Biotec Group Co., Ltd | For profit | 2 | 0 | 2 | 2019 |
| National Vaccine and Serum Institute, China | For profit | 2 | 2 | 2 | 2019 |
| Zhengzhou University | Academic/Hospital | 2 | 0 | 2 | 2019 |
| Ghent University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Icon Genetics | For profit | 1 | 1 | 1 | 2020 |
| Vaxart | For profit | 1 | 1 | 1 | 2022 |
8 organizations
Page 1 / 1